02617 藥捷安康－Ｂ
TRANSTHERA-B
TRANSTHERA-B
| Listing Date | 2025/06/23 |
| Listing Price | 13.150 |
Subscription Result
- Subscription Rate3,419.87x
- Guarantee One Lot Size--
- One Lot Success Rate0.8%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
TransThera Sciences (Nanjing), Inc. is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Group have discovered and developed one Core Product, built a pipeline of five clinical stage product candidates and one preclinical stage product candidate.
--
Tinengotinib (TT-00420), the Group’s Core Product, is an internally discovered and developed, registrational clinical stage, unique MTK inhibitor for the treatment of drug-resistant, relapsed or refractory cancers. Tinengotinib targets three key pathways including FGFR/VEGFR, JAK and Aurora.
--
As of June 4, 2025, the Group was undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China and the other as a multi-regional clinical trial involving the U.S..
--
The Group’s global partners comprise leading pharmaceutical companies, including LG Chem, Roche, Teijin, and EA Pharma. The Group derived revenue primarily from milestone payments from LG Chem in connection with the out-licensed TT-01025.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 15.28M H shares |
| No. of International Offer Shares | 12.22M H shares |
| No. of HK Offer Shares | 3.06M H shares |
| Offer Price | $13.15 |
| Stock Code | 2617 |
| Sponsor(s) | CITIC Securities (Hong Kong) Limited, Huatai Financial Holdings (Hong Kong) Limited |
| Underwriter(s) | CLSA Limited, Huatai Financial Holdings (Hong Kong) Limited, BOCOM International Securities Limited, BOCI Asia Limited, CMB International Capital Limited, SPDB International Capital Limited, TradeGo Markets Limited |
TIME TABLE
| Application Period | Jun 13 (Fri) - noon, Jun 18 (Wed) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jun 20 (Fri) |
| Result Announcement Date | On or before Jun 20 (Fri) |
| Result Announcement Date | On or before Jun 23 (Mon) |
| Dealings in Shares commence on | Jun 23, 2025. (Mon) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $13.15 |
| Capitalization | 5.22B |
| NAV / share ($) | $1.9 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 13.15, the net proceeds raised would be HKD 161.30M, of which |
| 90% : fund the research and development of Core Product Tinengotinib |
| 10% : Working capital |
IPO NEWS
| 23/06/2025 16:08 |
| {New Stock}TRANSTHERA-B(02617) ends up 78.71% at HK$23.5 |
| 23/06/2025 09:20 |
| {New Stock}TRANSTHERA-B(02617) opens up 64.64% at HK$21.65 |
| 20/06/2025 18:35 |
| {New Stock}TRANSTHERA-B(02617) ends up 68.82% on grey market |
| 20/06/2025 16:20 |
| {New Stock}TRANSTHERA-B up 59.7% at HK$21 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).